US Drug Recall Register
Class II · Moderate risk Ongoing Initiated Jul 22, 2025 (14 months ago)

Lorazepam Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

What was recalled

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

Recalling firm
Hikma Pharmaceuticals USA Inc.
NDC code
0641-6044-25
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0551-2025

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Lorazepam recalls

See all
Class II · Moderate risk Ongoing

Lorazepam 0.5 mg per 0.25 mL Oral Syringe

Reason Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.

Safecor Health, LLC D-0253-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0228-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0227-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0226-2025
Class II · Moderate risk Terminated

Lorazepam Injection

Reason Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.

Hikma Pharmaceuticals USA Inc. NDC 0641-6044-01 D-0574-2023